WO2013005514A1 - 経口摂取用肌改善剤 - Google Patents

経口摂取用肌改善剤 Download PDF

Info

Publication number
WO2013005514A1
WO2013005514A1 PCT/JP2012/064211 JP2012064211W WO2013005514A1 WO 2013005514 A1 WO2013005514 A1 WO 2013005514A1 JP 2012064211 W JP2012064211 W JP 2012064211W WO 2013005514 A1 WO2013005514 A1 WO 2013005514A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
lingonberry
amla
extract
oral intake
Prior art date
Application number
PCT/JP2012/064211
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
太郎 内山
Original Assignee
株式会社 資生堂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社 資生堂 filed Critical 株式会社 資生堂
Priority to CN201280026508.8A priority Critical patent/CN103648514B/zh
Publication of WO2013005514A1 publication Critical patent/WO2013005514A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present invention relates to an oral intake skin-improving agent, an oral intake collagen production promoter, and a food and drink containing plant bodies of Lingonberry (Vaccinium vitis-idaea) and Amla (Phyllanthus emblica or Emblica officinale) or extracts thereof.
  • Lingonberry Vaccinium vitis-idaea
  • Amla Physical vitis-idaea
  • women's cosmetic concerns include an increase in skin wrinkles and sagging with aging. And it is known that such skin wrinkles and sagging are caused by a decrease in collagen production ability of dermal fibroblasts.
  • Patent Document 1 In order to promote the production of collagen, an external preparation for skin containing various plant extracts has been developed (Patent Document 1).
  • the active ingredient is absorbed percutaneously and fibroblasts are used. Therefore, depending on the active ingredient, the absorbability into the skin becomes a problem, and it cannot be said that a sufficient effect is obtained.
  • Collagen production promoters containing Amla extract are known as foods that enhance collagen production ability (Patent Document 2). By adding other ingredients to this, collagen production is further promoted, In addition, it is expected to develop a skin-improving agent for oral ingestion that can improve the elasticity and smoothness of the skin of the whole body and make the wrinkles and crease lines inconspicuous, and has a high skin-improving effect.
  • the extract of lingonberry also known as bilberry
  • Lingonberry also known as cowberry
  • the object of the present invention is to improve the skin production for natural ingestion with high safety and natural origin, which is excellent in the effect of improving the skin elasticity by promoting collagen production ability by ingestion. It is to provide an agent, a collagen production promoter for oral intake, and a food and drink.
  • the present invention is characterized by containing a plant body of Lingonberry and Amla or an extract thereof, and is a skin for oral consumption intended to improve skin elasticity, smoothness, wrinkles, and frying lines. It is an improving agent.
  • the present invention is a collagen production promoter for oral consumption characterized by containing plant bodies of Lingonberry and Amla or extracts thereof.
  • the present invention is a food or drink characterized by containing plant bodies of Lingonberry and Amla or extracts thereof.
  • the skin-improving agent for oral intake of the present invention when continuously ingested, the amount of collagen is increased, and the elasticity of the skin is improved, thereby improving the elasticity and smoothness of the skin over the whole body.
  • aging of the skin due to aging can be improved, for example, wrinkles and tangled lines become inconspicuous.
  • the skin improving agent for oral intake of the present invention contains a plant body of an edible natural plant or an extract thereof as an active ingredient, it is highly safe and enables continuous ingestion.
  • the form at the time of ingestion can be set according to various preferences, and it can be used as a food or drink or an oral medicine.
  • Vaccinium lingonberry Vaccinium vitis-idaea
  • euphorbiaceae Emblica Amla Plant body obtained from Emblica officinale
  • its extract is contained as an active ingredient.
  • Lingonberry (Vaccinium vitis-idaea) is also known as bilberry, and is known to be abundant in the Arctic Circle of Canada and Canada, and is rich in vitamin C and citric acid. Fruits are eaten raw and are commonly used in processed foods such as juice and jam.
  • the part of the lingonberry used in the present invention is not particularly limited, and may be arbitrarily used such as fruits (immature fruit, ripe fruit, dried fruit), leaves, tuberous roots, flowers, seeds and the like. Of these, fruits are preferably used.
  • the lingon berry used in the present invention can be used as raw or dried, but is preferably used as a dry powder or a solvent extract from the viewpoint of usability and formulation.
  • a method for obtaining a dry powder various parts of plants (fruits, leaves, tuberous roots, flowers, seeds, etc.) or whole plants are shredded or pulverized, and then dried or chopped or ground after the plants are dried. There is a method to obtain a dry powder. Moreover, after chopping or grinding
  • the extract of lingonberry can be obtained by a conventional method. For example, after the lingonberry is dried as necessary, it is immersed in an extraction solvent for a certain period of time, or is contacted with an extraction solvent that is heated to reflux, and then filtered. It can be obtained by concentrating.
  • the extraction solvent any solvent that is usually used for extraction can be used, and examples thereof include water, methanol, ethanol, propylene glycol, 1,3-butylene glycol, glycerol, and other alcohols, chloroform, dichloroethane, four Organic solvents such as carbon chloride, acetone and ethyl acetate can be used alone or in combination.
  • the extract obtained by extraction with the above solvent is used as it is, or concentrated extracts are used, or these extracts are adsorbed, for example, an ion exchange resin is used to remove impurities, or porous polymers (for example, Amberlite XAD- After adsorbing on the column of 2), elution with methanol or ethanol and concentration can also be used. Further, a partitioning method, for example, an extract extracted with water / ethyl acetate can be used.
  • the lingonberry extract is commercially available, for example, as “Lingonberry extract” (manufactured by Oriza Oil Chemical Co., Ltd.), and these commercially available products may be used.
  • Amla (Phyllanthus emblica or Emblica officinale) used in the present invention is a deciduous sub-tall tree belonging to the genus Emblica, and is distributed from India to Malaysia and southern China, and is considered to be the origin of India .
  • Amla has a unique name depending on each region or language, and is also called, for example, citrus citrus, oil citrus, ammarok, malach, Indian gooseberry, and the like.
  • the use site of Amla is not particularly limited, and can be used arbitrarily such as fruits (immature fruits, ripe fruits, dried fruits), leaves, tuberous roots, flowers, seeds, among which fruits are preferably used. .
  • Amla can be used raw or dried, but it is preferably used as a dry powder or solvent extract from the viewpoints of usability and formulation.
  • the method for obtaining the dry powder or the extract is not particularly limited, and the method described in the above lingon berry can be employed.
  • Amla extract is also commercially available, for example, as “San Amla” from Taiyo Kagaku Co., Ltd., and these commercially available products may be used.
  • the skin-improving agent for oral intake of the present invention improves the elasticity of the skin by promoting the ability to produce collagen in fibroblasts, and as a result, the elasticity and smoothness of the skin. Improves wrinkles and crease lines, making it less effective in suppressing skin aging due to aging.
  • the oral intake skin-improving agent and oral intake collagen production promoter of the present invention can be blended in various foods and drinks and taken as a food for improving skin, or administered as a pharmaceutical preparation.
  • the food and drink of the present invention can be obtained by blending lingonberry and amla plants or extracts thereof into various foods and drinks, but in the mass production process, the above-mentioned skin improving agent for oral intake or collagen for oral intake
  • a food / beverage product having a skin improvement effect can be efficiently obtained by using the production promoter as an in-process product and blending it into various food / beverage products.
  • the amount of Lingonberry and Amla to be ingested (administered) can be appropriately determined according to the method of ingestion (administration), dosage form, etc., but the amount of ingestion (administration) per day can be determined in terms of dry mass.
  • 0.1 mg to 10 g preferably 1 to 1000 mg, most preferably 10 to 100 mg for Amla, and 0.1 mg to 10 g, preferably 1 to 1000 mg, most preferably 10 to 100 mg for Amla. It is desirable.
  • additives can be arbitrarily selected and used as necessary.
  • functional materials, excipients, and flavoring agents can be included.
  • Functional materials include various vitamins such as pantothenic acid, folic acid and biotin, various minerals such as zinc, calcium, magnesium and iron, amino acids, oligosaccharides, propolis, royal jelly, ginkgo biloba, turmeric, EPA, DHA, coenzyme Q10, Chondroitin, lactic acid bacteria, lactoferrin, isoflavone, prunes, chitin, chitosan, glucosamine, ⁇ -lipoic acid, agaricus, garcinia, propolis, collagen, astaxanthin, forthrin, catechin, sesamin, ceramide, moroheiya, spirulina, cat's claw, etc. . These functional materials can be used alone or in combination of two or more.
  • the excipient may be anything that is usually used when it is in the desired dosage form, for example, starches such as wheat starch, rice starch, corn starch, potato starch, dextrin, cyclodextrin, and crystalline celluloses. , Sugars such as lactose, glucose, sugar, reduced maltose, starch syrup, fructooligosaccharide, emulsified oligosaccharide, and sugar alcohols such as sorbitol, erythritol, xylitol, lactitol, mannitol. These excipients can be used alone or in combination of two or more.
  • starches such as wheat starch, rice starch, corn starch, potato starch, dextrin, cyclodextrin, and crystalline celluloses.
  • Sugars such as lactose, glucose, sugar, reduced maltose, starch syrup, fructooligosaccharide, emulsified oligosaccharide
  • various fruit juice extracts such as Bontang extract, lychee extract and yuzu extract, various fruit juices such as apple juice, orange juice and lemon juice, various flavors such as peach flavor, ume flavor and yogurt flavor, acesulfame K, sucralose , Erythritol, oligosaccharides, mannose, xylitol, isomerized sugars, and other sweeteners, citric acid, malic acid, tartaric acid, gluconic acid, and other acidulants, green tea, oolong tea, banaba tea, Tochu tea, iron kannon tea, pearl barley Various tea ingredients such as tea, amacha mul tea, macomo tea, and kelp tea are listed. These taste agents can be used alone or in combination of two or more.
  • colorants preservatives, thickeners, binders, disintegrants, dispersants, stabilizers, gelling agents, antioxidants, surfactants, preservatives, pH adjusters, etc.
  • a known one to be used can be appropriately selected and used.
  • liquid, solid, granular, granular, pasty, gel, and the like can be arbitrarily selected.
  • foods and beverages include, for example, fruit juice beverages, vegetable juices, soft drinks, beverages such as tea, soups, pudding, yogurt, cake premix products, confectionery, cookies, candy, gummi, gum, and other general processing
  • food supplements such as drinks, foods and drinks for specified health use, functional foods and drinks, health foods and drinks, and the like. However, it is not limited to these examples.
  • the dosage form can be appropriately selected.
  • a solid preparation such as a tablet, granule, powder, capsule, etc. , Syrups and other liquid preparations, etc.
  • These pharmaceutical preparations include commonly used binders, disintegrants, thickeners, dispersants, reabsorption accelerators, corrigents, buffers, interfaces Excipients such as activators, solubilizers, preservatives, emulsifiers, tonicity agents, stabilizers and pH adjusters may be used as appropriate.
  • Test 1 “Measurement of collagen production ability” (Test method) 1. Human dermal fibroblasts were seeded on a 24-well plate, and the culture was continued in a DMEM culture medium containing 10% FBS. 2. After confirming the confluent state, the medium was replaced with 0.5 mL of DMEM culture medium containing each sample and incubated at 37 ° C. for 72 hours. 3. After incubation, the collagen concentration in the culture broth was measured using the ELISA method.
  • Statistic processing was performed to verify whether there was a difference between groups based on the collected samples. If the significance (p) indicated by the test result is 5% (p ⁇ 0.05), it is said that there is a significant difference between the data items (referred to as variables) used in the test. If p is less than 10% (p ⁇ 0.1), it is said that there is a significant trend difference between the data items (referred to as variables) used in the test. A significant difference and a significant trend difference mean that a difference has occurred for some reason. When conducting a biological test, whether or not there is a significant difference in the end is a technique for deriving whether there is a change between groups. Statistical analysis was performed at Tukey.
  • FIG. 1 is a graph showing the measurement results of collagen production ability of Samples 1 to 4 described above. From the results of FIG. 1, sample 4 (containing Lingonberry and Amla) showed a significant difference (p ⁇ 0.001) in collagen production ability compared to sample 1 (control). Sample 4 (containing Lingonberry and Amla) had a tendency (p ⁇ 0.10) to differ in collagen production ability from Sample 2 (amla alone). From this, it was confirmed that the skin improvement agent of this invention is excellent in the effect which improves collagen production by the synergistic effect of Lingonberry and Amla.
  • Table 1 shows the formulation of the test sample (drink).
  • Test 2 “Measurement of skin viscoelasticity” (Test method) After the continuous test (8 weeks after taking), the skin viscoelasticity of the paneler's back skin was measured using a cutometer (Courage + Khazaka).
  • the cute meter is a device that evaluates changes in the skin after suction at a constant pressure, and can obtain graph data as shown in FIG.
  • the numerical values for R0 to R8 and F3 shown in the graph respectively indicate the following physical properties.
  • R0 Easiness of pulling (It is better to pull fully ⁇ The higher the value, the better)
  • R1 Ease of returning to the original position (It is better to return to the original position ⁇
  • R3 Easiness of pulling (It is better to pull as much as possible ⁇
  • Group D (Lingonberry + Amla) was excellent in skin viscoelasticity, and significant differences were observed in viscoelasticity R0, R3, R8 and F3 compared to Group A (placebo).
  • Group D (Lingonberry + Amla) showed a significant difference (p ⁇ 0.05) in R8 and a trend difference (p ⁇ 0.10) in R0, R3 and F3 compared to Group C (Lingonberry). From this, it was confirmed that the skin improving agent or the like of the present invention is excellent in the effect of improving the elasticity of the skin and improving the skin elasticity.
  • Test 3 "Evaluation of wrinkles in the corner of the eye” (Test method) The eyes were photographed on the start date of the continuous test and 8 weeks after the start of the continuous test (the test end date). A dermatologist performed a photo judgment using a wrinkle grade standard photograph on the photographs at each time point, and scored with a score of 1 ⁇ 4 value.
  • ⁇ Wrinkle visual criteria> Visual evaluation using wrinkle grade standard photographs (8 levels of wrinkle grades 0 to 7) (Japan Cosmetics Society Cosmetic Function Evaluation Method Guidelines), with a 1/4 value score (eg 3.25, 3.5, etc.) Scored. Wrinkle determination was performed by a dermatologist. “Score: Criteria” Grade 0: No wrinkles Grade 1: Slightly unclear shallow wrinkles are observed Grade 2: Clear shallow wrinkles are slightly recognized Grade 3: Clear shallow wrinkles are observed Grade 4: Clear shallow wrinkles Slightly deep wrinkles are observed Grade 5: Slightly deep wrinkles are observed Grade 6: Clear deep wrinkles are recognized Grade 7: Extremely deep wrinkles are observed
  • FIG. 7 is a graph showing the results of the degree of wrinkle improvement.
  • Group D Lionberry + Amla
  • p ⁇ 0.01 was observed with respect to Group A (placebo).
  • the tendency difference (p ⁇ 0.10) was recognized by the D group (Lingonberry + Amla) also for the C group (Lingonberry). From this, it was confirmed that the skin improvement agent of this invention is excellent in the effect which improves the wrinkle of skin.
  • Test 4 “Questionnaire Evaluation” (Test method) 1 day, 3 days, 7 days, 14 days, 28 days, and 56 days after the start of the continuous test. A questionnaire survey was conducted on “feel”.
  • VAS abbreviation for visual analog scale
  • FIG. 8 is a graph showing the results of improvement obtained by a questionnaire survey on “Horoi Line”, FIG. 9 “Forehead Wrinkles”, and FIG. 10 “Smooth Skin Feel”.
  • * (P ⁇ 0.05) and + (p ⁇ 0.10) in the graph are portions where a significant difference or a tendency difference is recognized with respect to the group A (placebo).
  • the significant difference (p ⁇ 0.05) and the trend difference (p ⁇ 0.10) between the groups to be compared for each survey date are indicated by ⁇ and ⁇ , respectively. From these results, Group D (Lingonberry (RB) + Amla) is excellent in improving the frying line, improving the wrinkle of the forehead, and improving the smooth feeling of the skin, as shown in FIGS.
  • Group A placebo
  • Group D Lidonberry (RB) + Amla
  • Group C Lionberry (RB)
  • FIG. 11 shows the results of a questionnaire regarding hands and arms conducted 56 days after taking.
  • Group D Lionberry + Amla
  • Group D shows an excellent improvement effect, especially “Moisturizing”, “Smoothness”, “Smoothness”, “ There is a significant difference * (p ⁇ 0.05) or a tendency difference + (p ⁇ 0.10) with respect to Group A (placebo) in "Ease of pillow marks", “Skin itching” and “Skin transparency” Improvement effect was observed. From this, it was confirmed that the skin improving agent or the like of the present invention has an excellent skin improving effect on parts other than the face.
PCT/JP2012/064211 2011-07-06 2012-05-31 経口摂取用肌改善剤 WO2013005514A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280026508.8A CN103648514B (zh) 2011-07-06 2012-05-31 经口摄取用肌肤改善剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011150116A JP4917180B1 (ja) 2011-07-06 2011-07-06 経口摂取用肌改善剤
JP2011-150116 2011-07-06

Publications (1)

Publication Number Publication Date
WO2013005514A1 true WO2013005514A1 (ja) 2013-01-10

Family

ID=46243752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/064211 WO2013005514A1 (ja) 2011-07-06 2012-05-31 経口摂取用肌改善剤

Country Status (4)

Country Link
JP (1) JP4917180B1 (zh)
CN (1) CN103648514B (zh)
TW (2) TWI586376B (zh)
WO (1) WO2013005514A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6397550B1 (ja) * 2017-09-12 2018-09-26 株式会社 資生堂 体質改善剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4917180B1 (ja) * 2011-07-06 2012-04-18 株式会社 資生堂 経口摂取用肌改善剤
JP5777209B2 (ja) * 2011-08-12 2015-09-09 株式会社 資生堂 コラーゲン産生促進剤および食品組成物
JP2015096488A (ja) * 2013-10-10 2015-05-21 康二 嘉島 終末糖化物質生成抑制方法
JP6332941B2 (ja) * 2013-11-01 2018-05-30 株式会社東洋発酵 美容健康用経口組成物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002193738A (ja) * 2000-10-05 2002-07-10 L'oreal Sa 皮膚老化の徴候を処置する組成物における、少なくとも１種のツツジ科植物の少なくとも１種の抽出物の使用
JP2003012531A (ja) * 2001-07-06 2003-01-15 Ichimaru Pharcos Co Ltd コラゲナーゼ活性阻害剤又は化粧料組成物
WO2006134583A1 (en) * 2005-06-17 2006-12-21 Oriflame Global Technical Centre, Ltd. Cosmetic compositions containing lingonberry (vaccinium vitis idea) extracts
JP2008156287A (ja) * 2006-12-25 2008-07-10 Sanki Shoji Kk コラーゲン産生促進剤
JP2009184997A (ja) * 2008-02-08 2009-08-20 B & C Laboratories Inc コラーゲン産生促進剤
JP2010531816A (ja) * 2007-07-04 2010-09-30 ベイジン ギンコ グループ コケモモ抽出物含有の美容組成物及びその応用
JP4917180B1 (ja) * 2011-07-06 2012-04-18 株式会社 資生堂 経口摂取用肌改善剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1210016A (zh) * 1997-08-29 1999-03-10 王树岐 一种抗烟草保健品
JP2005306850A (ja) * 2004-03-24 2005-11-04 Kose Corp 抗皮膚障害剤、及びこれを含有する皮膚外用剤
CN101543525B (zh) * 2008-03-28 2012-11-21 北京绿色金可生物技术股份有限公司 一种含红豆越橘提取物的美容组合物及其应用
JP2011102270A (ja) * 2009-11-11 2011-05-26 Rohto Pharmaceutical Co Ltd 抗糖化剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002193738A (ja) * 2000-10-05 2002-07-10 L'oreal Sa 皮膚老化の徴候を処置する組成物における、少なくとも１種のツツジ科植物の少なくとも１種の抽出物の使用
JP2003012531A (ja) * 2001-07-06 2003-01-15 Ichimaru Pharcos Co Ltd コラゲナーゼ活性阻害剤又は化粧料組成物
WO2006134583A1 (en) * 2005-06-17 2006-12-21 Oriflame Global Technical Centre, Ltd. Cosmetic compositions containing lingonberry (vaccinium vitis idea) extracts
JP2008156287A (ja) * 2006-12-25 2008-07-10 Sanki Shoji Kk コラーゲン産生促進剤
JP2010531816A (ja) * 2007-07-04 2010-09-30 ベイジン ギンコ グループ コケモモ抽出物含有の美容組成物及びその応用
JP2009184997A (ja) * 2008-02-08 2009-08-20 B & C Laboratories Inc コラーゲン産生促進剤
JP4917180B1 (ja) * 2011-07-06 2012-04-18 株式会社 資生堂 経口摂取用肌改善剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANVORACHOTE PITHI ET AL.: "Type I pro-collagen promoting and anti-collagenase activities of Phyllanthus emblica extract in mouse fibroblasts", J COSMET SCI, vol. 60, no. 4, 2009, pages 395 - 403 *
SHIN'ICHI MATSUMURA: "Polyphenol no Kinosei to Riyo 5 Amla Kajitsu no Kinosei Oyobi sono Genjo ni Tsuite", FOOD PROCESSING AND INGREDIENTS, vol. 35, no. 6, 2000, pages 19 - 21 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6397550B1 (ja) * 2017-09-12 2018-09-26 株式会社 資生堂 体質改善剤
WO2019054313A1 (ja) * 2017-09-12 2019-03-21 株式会社資生堂 体質改善剤

Also Published As

Publication number Publication date
CN103648514A (zh) 2014-03-19
TW201720424A (zh) 2017-06-16
JP2013014561A (ja) 2013-01-24
TWI586376B (zh) 2017-06-11
JP4917180B1 (ja) 2012-04-18
CN103648514B (zh) 2016-11-16
TW201302243A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
JP4163631B2 (ja) 無辛味品種トウガラシの発酵組成物及びその利用
JP4917180B1 (ja) 経口摂取用肌改善剤
KR101017594B1 (ko) 퀘르세틴 함량이 증가된 발효 양파 추출물의 제조방법
TWI430754B (zh) 高γ－胺基丁酸含有物之製造方法
KR101474998B1 (ko) 피부 주름 생성 억제 및 주름 개선 활성을 갖는 백차 추출물을 함유하는 조성물
JP2004315512A (ja) 機能性組成物
KR102437419B1 (ko) 숙취해소용 조성물
JP4352030B2 (ja) 健康食品
KR20160060834A (ko) 식물 추출물을 포함하는 케피어 그레인 배지 조성물 및 그 배지 조성물에 의한 발효 배양물을 포함하는 피부 상태 개선용 조성물
JP2010184886A (ja) 新規化合物
KR102171334B1 (ko) 약콩 발효물을 포함하는 피부 개선용 조성물
JP5832714B2 (ja) チロシナーゼ活性阻害剤及びメラニン産生抑制剤
KR20070113330A (ko) 곰피 추출물을 포함하는 피부외용제 조성물
KR102106440B1 (ko) 블루베리 및 흑미 추출물 배양 유산균을 포함하는 피부상태 개선용 조성물
KR20170053536A (ko) 도라지를 유효성분으로 포함하는 기관지질환 및 고지혈증 예방 효능의 도라지 함유 음료 및 이의 제조방법
KR102100989B1 (ko) 구절초 및 발효옻을 이용한 이너뷰티 음료의 제조방법
JP6397550B1 (ja) 体質改善剤
KR20170077980A (ko) 큰도꼬마리 어린순 추출물을 함유하는 항산화 또는 항노화용 조성물
JP5422137B2 (ja) 美白剤、チロシナーゼ活性阻害剤、メラニン産生抑制剤、及び美白用皮膚外用剤
KR20160111126A (ko) 감 발효물을 이용한 아토피성 피부염 개선용 조성물
JP4608017B1 (ja) 経口摂取用毛穴縮小剤
KR102012170B1 (ko) 바나나, 체리 및 호두의 혼합 추출물을 포함하는 피부 노화 방지 또는 개선용 조성물
JP7262319B2 (ja) メラニン生成抑制剤、及びメラニン生成抑制剤の製造方法
KR102537844B1 (ko) 마리골드 추출물에 모유 유산균으로 생물전환 시킨 성분을 함유하는 항균, 항산화 및 항염증 활성을 갖는 조성물
JP2013116887A (ja) 経口用育毛剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12807582

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12807582

Country of ref document: EP

Kind code of ref document: A1